Dataset Information


Preoperative inflammation markers and IDH mutation status predict glioblastoma patient survival.

ABSTRACT: Recent studies suggest that inflammation response biomarkers are prognostic indicators of solid tumor outcomes. Here, we quantify the prognostic value of the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR) in glioblastomas (GBMs), taking into consideration the role of the isocitrate dehydrogenase (IDH) mutation status. We examined 141 primary glioblastomas (pGBMs) and 25 secondary glioblastomas (sGBMs). NLRs, PLRs, and LMRs were calculated before surgery. IDH mutations were detected immunohistochemically after tumor resection, and patients' clinical outcomes were analyzed after classification into GBM, pGBM, and IDH-wild type glioblastoma (IDH-wt GBM) groups. To make comparisons, we set cutoffs for NLR, PLR and LMR of 4.0, 175.0, and 3.7, respectively. In a multivariate analysis, both NLR (HR=1.712, 95% CI 1.026-2.858, p=0.040) and PLR (HR=2.051, 95% CI 1.288-3.267, p=0.002) had independent prognostic value. While a low NLR was associated with a better prognosis only in the IDH-wt GBM group, PLR was predictive of patient survival in the GBM, pGBM, and IDH-wt GBM groups. By contrast, LMR exhibited no prognostic value for any of the 3 types of GBM.


PROVIDER: S-EPMC5564834 | BioStudies | 2017-01-01

SECONDARY ACCESSION(S): 10.18632/oncotarget.15235

REPOSITORIES: biostudies

Similar Datasets

2018-01-01 | S-EPMC6103192 | BioStudies
2019-01-01 | S-EPMC6781693 | BioStudies
2017-01-01 | S-EPMC5601158 | BioStudies
2019-01-01 | S-EPMC6380854 | BioStudies
1000-01-01 | S-EPMC6062056 | BioStudies
2017-01-01 | S-EPMC5538703 | BioStudies
2017-01-01 | S-EPMC5601775 | BioStudies
1000-01-01 | S-EPMC5711862 | BioStudies
2020-01-01 | S-EPMC7046751 | BioStudies
1000-01-01 | S-EPMC5907660 | BioStudies